In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price target of $82.00.
Sam Slutsky has given his Buy rating due to a combination of factors including the promising data from CG Oncology’s BOND-003 trial involving cretostomogene, a targeted oncolytic virus for treating HR BCG-unresponsive NMIBC. The final data from Cohort C, which will be presented at an upcoming conference, is expected to provide significant insights into the treatment’s efficacy. Moreover, the ongoing debate between cretostomogene and TAR-200 as treatment options suggests that both have the potential to be commercially successful, indicating a strong market opportunity for CG Oncology.
Additionally, the company has several upcoming milestones, such as the release of topline data from other cohorts and the filing of a Biologics License Application (BLA) for cretostomogene, which could further enhance its market position. The company’s financial metrics, including its cash burn rate and share structure, also support a positive outlook. These elements combined provide a solid foundation for the Buy rating, reflecting confidence in CG Oncology’s future growth prospects.
According to TipRanks, Slutsky is an analyst with an average return of -12.3% and a 28.61% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Immunovant, Astria Therapeutics, and Abivax SA Sponsored ADR.